S&P 500   4,207.27 (-0.07%)
DOW   33,336.67 (+0.08%)
QQQ   324.63 (-0.40%)
AAPL   168.71 (-0.31%)
MSFT   287.21 (-0.67%)
META   177.50 (-0.47%)
GOOGL   119.28 (-0.35%)
AMZN   140.88 (-1.27%)
TSLA   863.20 (-2.25%)
NVDA   179.88 (-0.60%)
NIO   20.77 (+3.59%)
BABA   94.94 (+2.72%)
AMD   98.30 (-0.76%)
MU   62.33 (+1.51%)
T   18.05 (+0.22%)
CGC   3.15 (-4.26%)
GE   78.88 (+2.26%)
F   15.83 (+2.13%)
DIS   117.79 (+4.77%)
AMC   25.45 (+7.52%)
PYPL   99.11 (+0.20%)
PFE   48.29 (-3.32%)
NFLX   242.81 (-0.53%)
S&P 500   4,207.27 (-0.07%)
DOW   33,336.67 (+0.08%)
QQQ   324.63 (-0.40%)
AAPL   168.71 (-0.31%)
MSFT   287.21 (-0.67%)
META   177.50 (-0.47%)
GOOGL   119.28 (-0.35%)
AMZN   140.88 (-1.27%)
TSLA   863.20 (-2.25%)
NVDA   179.88 (-0.60%)
NIO   20.77 (+3.59%)
BABA   94.94 (+2.72%)
AMD   98.30 (-0.76%)
MU   62.33 (+1.51%)
T   18.05 (+0.22%)
CGC   3.15 (-4.26%)
GE   78.88 (+2.26%)
F   15.83 (+2.13%)
DIS   117.79 (+4.77%)
AMC   25.45 (+7.52%)
PYPL   99.11 (+0.20%)
PFE   48.29 (-3.32%)
NFLX   242.81 (-0.53%)
S&P 500   4,207.27 (-0.07%)
DOW   33,336.67 (+0.08%)
QQQ   324.63 (-0.40%)
AAPL   168.71 (-0.31%)
MSFT   287.21 (-0.67%)
META   177.50 (-0.47%)
GOOGL   119.28 (-0.35%)
AMZN   140.88 (-1.27%)
TSLA   863.20 (-2.25%)
NVDA   179.88 (-0.60%)
NIO   20.77 (+3.59%)
BABA   94.94 (+2.72%)
AMD   98.30 (-0.76%)
MU   62.33 (+1.51%)
T   18.05 (+0.22%)
CGC   3.15 (-4.26%)
GE   78.88 (+2.26%)
F   15.83 (+2.13%)
DIS   117.79 (+4.77%)
AMC   25.45 (+7.52%)
PYPL   99.11 (+0.20%)
PFE   48.29 (-3.32%)
NFLX   242.81 (-0.53%)
S&P 500   4,207.27 (-0.07%)
DOW   33,336.67 (+0.08%)
QQQ   324.63 (-0.40%)
AAPL   168.71 (-0.31%)
MSFT   287.21 (-0.67%)
META   177.50 (-0.47%)
GOOGL   119.28 (-0.35%)
AMZN   140.88 (-1.27%)
TSLA   863.20 (-2.25%)
NVDA   179.88 (-0.60%)
NIO   20.77 (+3.59%)
BABA   94.94 (+2.72%)
AMD   98.30 (-0.76%)
MU   62.33 (+1.51%)
T   18.05 (+0.22%)
CGC   3.15 (-4.26%)
GE   78.88 (+2.26%)
F   15.83 (+2.13%)
DIS   117.79 (+4.77%)
AMC   25.45 (+7.52%)
PYPL   99.11 (+0.20%)
PFE   48.29 (-3.32%)
NFLX   242.81 (-0.53%)
NASDAQ:BIIB

Biogen - BIIB Stock Forecast, Price & News

$220.00
-1.04 (-0.47%)
(As of 08/11/2022 04:11 PM ET)
Add
Compare
Today's Range
$216.93
$222.61
50-Day Range
$191.53
$221.04
52-Week Range
$187.16
$351.86
Volume
30,284 shs
Average Volume
945,171 shs
Market Capitalization
$31.92 billion
P/E Ratio
15.69
Dividend Yield
N/A
Price Target
$252.44

Biogen MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.52 Rating Score
Upside/​Downside
15.7% Upside
$252.44 Price Target
Short Interest
Healthy
1.34% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.56
Upright™ Environmental Score
News Sentiment
0.20mentions of Biogen in the last 14 days
Based on 14 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
-0.79%
From $16.36 to $16.23 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.63 out of 5 stars

Medical Sector

119th out of 1,112 stocks

Biological Products, Except Diagnostic Industry

18th out of 175 stocks

BIIB stock logo

About Biogen (NASDAQ:BIIB) Stock

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Biogen Stock Up 1.6 %

BIIB Stock opened at $221.04 on Thursday. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.68 and a current ratio of 1.94. The business's 50 day moving average price is $209.10 and its two-hundred day moving average price is $209.18. Biogen has a fifty-two week low of $187.16 and a fifty-two week high of $351.86. The company has a market capitalization of $32.08 billion, a price-to-earnings ratio of 15.77, a price-to-earnings-growth ratio of 1.00 and a beta of 0.40.

Biogen (NASDAQ:BIIB - Get Rating) last released its quarterly earnings results on Wednesday, July 20th. The biotechnology company reported $5.25 earnings per share for the quarter, beating the consensus estimate of $4.09 by $1.16. The firm had revenue of $2.59 billion for the quarter, compared to analysts' expectations of $2.48 billion. Biogen had a return on equity of 22.36% and a net margin of 19.36%. The company's revenue was down 6.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $5.68 EPS. As a group, analysts forecast that Biogen will post 16.36 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently commented on BIIB. Oppenheimer increased their price target on shares of Biogen from $225.00 to $230.00 and gave the company an "outperform" rating in a report on Monday, July 18th. Robert W. Baird reiterated a "neutral" rating and set a $224.00 price objective on shares of Biogen in a research note on Tuesday, August 2nd. Truist Financial decreased their target price on shares of Biogen from $320.00 to $270.00 and set a "buy" rating for the company in a research report on Thursday, July 21st. SVB Leerink cut their price objective on shares of Biogen from $300.00 to $270.00 and set an "outperform" rating for the company in a report on Thursday, April 21st. Finally, StockNews.com raised shares of Biogen from a "buy" rating to a "strong-buy" rating in a research note on Wednesday, July 27th. Thirteen equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $257.36.

Receive BIIB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biogen and its competitors with MarketBeat's FREE daily newsletter.

BIIB Stock News Headlines

Tailor an Options Trading Strategy to Fit Your Needs
This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile. Take your trading to the next level with the Options Strategy Guide. pixel
Biogen (NASDAQ:BIIB) Stock Rating Reaffirmed by Robert W. Baird
Tailor an Options Trading Strategy to Fit Your Needs
This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile. Take your trading to the next level with the Options Strategy Guide. pixel
StockNews.com Upgrades Biogen (NASDAQ:BIIB) to Strong-Buy
UBS Group Trims Biogen (NASDAQ:BIIB) Target Price to $238.00
See More Headlines
Receive BIIB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biogen and its competitors with MarketBeat's FREE daily newsletter.

BIIB Company Calendar

Last Earnings
7/20/2022
Today
8/11/2022
Next Earnings (Estimated)
10/19/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:BIIB
CUSIP
09062X10
Employees
9,610
Year Founded
1978

Price Target and Rating

Average Stock Price Forecast
$252.44
High Stock Price Forecast
$400.00
Low Stock Price Forecast
$185.00
Forecasted Upside/Downside
+14.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.52
Research Coverage
27 Analysts

Profitability

Net Income
$1.56 billion
Pretax Margin
21.75%

Debt

Sales & Book Value

Annual Sales
$10.98 billion
Cash Flow
$27.47 per share
Book Value
$81.75 per share

Miscellaneous

Free Float
144,170,000
Market Cap
$31.92 billion
Optionable
Optionable
Beta
0.40

Social Links


Key Executives

  • Mr. Michel Vounatsos (Age 60)
    CEO & Director
    Comp: $3.11M
  • Mr. Michael R. McDonnell CPA (Age 58)
    Exec. VP & CFO
    Comp: $1.86M
  • Ms. Susan H. Alexander Esq. (Age 65)
    Exec. VP, Chief Legal Officer & Sec.
    Comp: $1.79M
  • Ms. Robin C. Kramer (Age 56)
    Sr. VP & Chief Accounting Officer
  • Ms. Nicole Murphy
    Head of Pharmaceutical Operations & Technology
  • Mr. Michael Hencke
    Head of Investor Relations
  • Ms. Natacha Gassenbach
    Chief Communication Officer & Head of Corp. Affairs
  • Dr. Ginger Gregory (Age 54)
    Exec. VP & Chief HR Officer
  • Dr. Anabella Villalobos Ph.D.
    Head of Biotherapeutics & Medicinal Sciences
  • Dr. Sanjay Jariwala
    Sr. VP of Worldwide Medical













BIIB Stock - Frequently Asked Questions

Should I buy or sell Biogen stock right now?

27 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last twelve months. There are currently 13 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BIIB shares.
View BIIB analyst ratings
or view top-rated stocks.

What is Biogen's stock price forecast for 2022?

27 equities research analysts have issued 12 month target prices for Biogen's stock. Their BIIB share price forecasts range from $185.00 to $400.00. On average, they predict the company's stock price to reach $252.44 in the next year. This suggests a possible upside of 14.9% from the stock's current price.
View analysts price targets for BIIB
or view top-rated stocks among Wall Street analysts.

How have BIIB shares performed in 2022?

Biogen's stock was trading at $239.92 at the beginning of 2022. Since then, BIIB stock has decreased by 8.4% and is now trading at $219.72.
View the best growth stocks for 2022 here
.

When is Biogen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, October 19th 2022.
View our BIIB earnings forecast
.

How were Biogen's earnings last quarter?

Biogen Inc. (NASDAQ:BIIB) issued its quarterly earnings data on Wednesday, July, 20th. The biotechnology company reported $5.25 earnings per share for the quarter, topping analysts' consensus estimates of $4.09 by $1.16. The biotechnology company had revenue of $2.59 billion for the quarter, compared to analysts' expectations of $2.48 billion. Biogen had a net margin of 19.36% and a trailing twelve-month return on equity of 22.36%. The company's revenue for the quarter was down 6.7% compared to the same quarter last year. During the same period in the previous year, the business posted $5.68 earnings per share.
Read the conference call transcript
.

What guidance has Biogen issued on next quarter's earnings?

Biogen issued an update on its FY 2022 earnings guidance on Wednesday, August, 3rd. The company provided earnings per share (EPS) guidance of $15.25-$16.75 for the period, compared to the consensus earnings per share estimate of $15.54. The company issued revenue guidance of $9.90 billion-$10.10 billion, compared to the consensus revenue estimate of $9.84 billion.

What is Michel Vounatsos' approval rating as Biogen's CEO?

394 employees have rated Biogen Chief Executive Officer Michel Vounatsos on Glassdoor.com. Michel Vounatsos has an approval rating of 86% among the company's employees. 72.0% of employees surveyed would recommend working at Biogen to a friend.

What other stocks do shareholders of Biogen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Amgen (AMGN), Walt Disney (DIS), Intel (INTC), Micron Technology (MU) and Boeing (BA).

What is Biogen's stock symbol?

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

Who are Biogen's major shareholders?

Biogen's stock is owned by a number of institutional and retail investors. Top institutional investors include Deutsche Bank AG (1.15%), Van ECK Associates Corp (0.65%), Sumitomo Mitsui Trust Holdings Inc. (0.45%), Assenagon Asset Management S.A. (0.44%), Swiss National Bank (0.44%) and Pictet Asset Management SA (0.35%). Insiders that own company stock include Alfred Sandrock, Brian S Posner, Michel Vounatsos and Stephen A Sherwin.
View institutional ownership trends
.

How do I buy shares of Biogen?

Shares of BIIB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biogen's stock price today?

One share of BIIB stock can currently be purchased for approximately $219.72.

How much money does Biogen make?

Biogen (NASDAQ:BIIB) has a market capitalization of $31.88 billion and generates $10.98 billion in revenue each year. The biotechnology company earns $1.56 billion in net income (profit) each year or $14.02 on an earnings per share basis.

How many employees does Biogen have?

The company employs 9,610 workers across the globe.

Does Biogen have any subsidiaries?

The following companies are subsidiares of Biogen: BIIB Colombia S.A.S., Biogen (Argentina) SRL, Biogen (Bermuda) Technologies Ltd., Biogen (Czech Republic) s.r.o., Biogen (Denmark) A/S, Biogen (RTP) Realty LLC, Biogen Australia PTY Ltd, Biogen Austria GmbH, Biogen B.V., Biogen Belgium N.V./S.A., Biogen Biotechnology (Shanghai) Co. Ltd, Biogen Brasil Produtos Farmaceuticos LTDA, Biogen Canada Inc., Biogen Chesapeake LLC, Biogen Chile Spa, Biogen Digital Health Inc., Biogen Estonia OU, Biogen Finland OY, Biogen Foundation Inc., Biogen France S.A.S., Biogen GmbH, Biogen Holding I LLC, Biogen Holding II LLC, Biogen Hong Kong Limited, Biogen Hungary KFT, Biogen Idec (Ireland) Ltd., Biogen Idec Biotech India Pvt. Ltd., Biogen Idec Limited, Biogen Idec Research Ltd., Biogen Idec Uruguay SA, Biogen International GmbH, Biogen International Holding Limited, Biogen International Neuroscience GmbH, Biogen Italia S.R.L., Biogen Japan Ltd., Biogen Korea LLC, Biogen Latvia SIA, Biogen Lithuania UAB, Biogen Luxembourg Holding S.a.r.l., Biogen MA Inc., Biogen Management Services GmbH, Biogen Manufacturing Holding LLC, Biogen Mexico S. DE R.L. DE C.V., Biogen NZ Biopharma Ltd., Biogen Netherlands B.V., Biogen New Ventures Inc., Biogen Norway AS, Biogen Pharma d.o.o., Biogen Pharma farmacevtska in biotehnoloska druzba d.o.o., Biogen Poland Sp. z.o.o., Biogen Portugal Sociedade Farmaceutica Unipessoal Lda., Biogen Realty Corporation, Biogen Realty Limited Partnership, Biogen SRO Inc., Biogen Slovakia s.r.o., Biogen Spain S.L., Biogen Sweden AB, Biogen Swiss Investments GmbH, Biogen Swiss Manufacturing GmbH, Biogen Switzerland AG, Biogen Switzerland Holdings GmbH, Biogen Taiwan Limited, Biogen Therapeutics Inc., Biogen Turkey Ilac Ticaret Limited Sirketi, Biogen U.S. Corporation, Biogen U.S. Limited Partnership, Biogen U.S. Pacific LLC, Biogen U.S. West Corporation, Conforma Therapeutics, Conforma Therapeutics Corporation, Convergence Pharmaceuticals, Convergence Pharmaceuticals Holdings Ltd., Convergence Pharmaceuticals Limited, Eidetica Biopharma GmbH, Fumapharm, IDEC Pharmaceuticals Corporation, NightstaRx Limited, Nightstar Europa Limited, Nightstar Inc., Nightstar Therapeutics Limited, Nightstar Therapeutics plc, Old Convergence Pharmaceuticals Limited, Panima Pharmaceuticals AG, Silver Acquisition Co. Ltd., Stromedix Inc., Stromedix Inc., Syntonix Pharmaceuticals Inc., TYSABRI, and Tungsten Bidco Limited.
Read More

When was Biogen founded?

Biogen was founded in 1978.

How can I contact Biogen?

Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The official website for the company is www.biogen.com. The biotechnology company can be reached via phone at (617) 679-2000, via email at ir@biogen.com, or via fax at 617-679-2617.

This page (NASDAQ:BIIB) was last updated on 8/11/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.